After much deliberation, this week a panel of experts advising the Food and Drug Administration voted against the approval of therapy-guided MDMA for treating PSTD.\nKennedy criticizes the panel for prohibiting PSTD patients from getting effective treatment and highlights the success of studies and clinical trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the high improvement rates reported by participants.\n\ufeffFollow Kennedy on Twitter:\xa0@KennedyNation\nKennedy Now Available on YouTube:\xa0https://bit.ly/4311mhD.\nLearn more about your ad choices. Visit megaphone.fm/adchoices